{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:12Z","timestamp":1786993452808,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jsps.2022.10.001","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T11:58:53Z","timestamp":1665143933000},"page":"1725-1735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics\u2019 impact"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6246-0841","authenticated-orcid":false,"given":"Ohoud A.","family":"Almadani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-2468","authenticated-orcid":false,"given":"Thamir M.","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2022.10.001_b0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.puhe.2015.11.010","article-title":"Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system","volume":"135","author":"Alguacil-Ramos","year":"2016","journal-title":"Public Health"},{"key":"10.1016\/j.jsps.2022.10.001_b0010","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.10.001_b0015","doi-asserted-by":"crossref","unstructured":"Bellavite, P., Puliyel, J., Keele, C.E., Monitoring, U., Chandler, R., 2020. Open Peer Review Causality assessment of adverse events following immunization: the problem of multifactorial pathology [version 2; peer review: 3 approved, 1 approved with reservations]. https:\/\/doi.org\/10.12688\/f1000research.22600.1.","DOI":"10.12688\/f1000research.22600.2"},{"key":"10.1016\/j.jsps.2022.10.001_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.idc.2017.11.005","article-title":"Updates on Influenza Vaccination in Children","volume":"32","author":"Campbell","year":"2018","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.jsps.2022.10.001_b0025","unstructured":"Centers for Disease Control and Prevention (CDC), 2014. Vaccine Testing and Approval Process | CDC [WWW Document]. URL https:\/\/www.cdc.gov\/vaccines\/basics\/test-approve.html (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0030","unstructured":"Centers for Disease Control and Prevention, 2011. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males \u2014 Advisory Committee on Immunization Practices (ACIP), 2011 [WWW Document]. URL https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6050a3.htm (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0035","unstructured":"Centers for Disease Control and Prevention, 2021. Immunization Basics | CDC [WWW Document]. URL https:\/\/www.cdc.gov\/vaccines\/vac-gen\/imz-basics.htm (accessed 9.1.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0040","unstructured":"Centers for Disease Control and Prevention, 2022. Ask the Experts about Pertussis Vaccines (DTaP, Tdap) - CDC experts answer Q&As [WWW Document]. URL https:\/\/www.immunize.org\/askexperts\/experts_per.asp (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0045","doi-asserted-by":"crossref","first-page":"P1.147","DOI":"10.1212\/WNL.86.16_supplement.P1.147","article-title":"Post-Vaccination Headache Reporting Trends According to the Vaccine Adverse Events Reporting System (VAERS) (P1.147)","volume":"86","author":"Cocores","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jsps.2022.10.001_b0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2471\/BLT.07.048025","article-title":"Safety profile of pneumococcal conjugate vaccines: systematic review of pre-and post-licensure data","volume":"86","author":"DeStefano","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jsps.2022.10.001_b0055","doi-asserted-by":"crossref","unstructured":"Dub\u00e9, E., Laberge, C., Guay, M., Bramadat, P., Roy, R., Bettinger, J.A., 2013. Human Vaccines & Immunotherapeutics Vaccine hesitancy An overview 1763\u20131773. https:\/\/doi.org\/10.4161\/hv.24657.","DOI":"10.4161\/hv.24657"},{"key":"10.1016\/j.jsps.2022.10.001_b0060","doi-asserted-by":"crossref","unstructured":"Fadare, J.O., Haazen, L., Lombardi, N., Crescioli, G., Bettiol, A., Tuccori, M., Rossi, M., Bonaiuti, R., Ravaldi, C., Levi, M., Mugelli, A., Ricci, S., Lippi, F., Azzari, C., Bonanni, P., Vannacci, A., 2019. Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy 10, 948. https:\/\/doi.org\/10.3389\/fphar.2019.00948.","DOI":"10.3389\/fphar.2019.00948"},{"key":"10.1016\/j.jsps.2022.10.001_b0065","unstructured":"FDA, 2005. Federal Register\u00a0:: Authorization of Emergency Use of Anthrax Vaccine Adsorbed for Prevention of Inhalation Anthrax by Individuals at Heightened Risk of Exposure Due to Attack With Anthrax; Extension; Availability [WWW Document]. URL https:\/\/www.federalregister.gov\/documents\/2005\/08\/03\/05-15233\/authorization-of-emergency-use-of-anthrax-vaccine-adsorbed-for-prevention-of-inhalation-anthrax-by (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0070","unstructured":"FDA, 2018. CFR - Code of Federal Regulations Title 21."},{"key":"10.1016\/j.jsps.2022.10.001_b0075","unstructured":"FDA, CBER, 2020. CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol."},{"key":"10.1016\/j.jsps.2022.10.001_b0080","unstructured":"FDA, CBER, 2021. Contains Nonbinding Recommendations Emergency Use Authorization for Vaccines to Prevent COVID-19 Guidance for Industry Preface Public Comment."},{"key":"10.1016\/j.jsps.2022.10.001_b0085","unstructured":"Fiore, A.E., Uyeki, T.M., Broder, K., Finelli, L., Euler, G.L., Singleton, J.A., Iskander, J.K., Wortley, P.M., Shay, D.K., Bresee, J.S., Cox, N.J., Centers for Disease Control and Prevention (CDC), 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59, 1\u201362."},{"key":"10.1016\/j.jsps.2022.10.001_b0090","unstructured":"Food and Drug Authority (FDA), 2001. Vaccine and Related Biological Product Guidances | FDA [WWW Document]. URL https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/vaccine-and-related-biological-product-guidances (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0095","unstructured":"Food and Drug Authority (FDA), 2016. What is a Serious Adverse Event? | FDA [WWW Document]. URL https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event (accessed 2.6.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0100","unstructured":"Food and Drug Authority (FDA), 2020. Emergency Use Authorization for Vaccines Explained | FDA [WWW Document]. URL https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/emergency-use-authorization-vaccines-explained (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0105","unstructured":"Food and Drug Authority, 2009. Gardasil Vaccine Safety | FDA [WWW Document]. URL https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/gardasil-vaccine-safety (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1542\/peds.93.5.747","article-title":"Universal Hepatitis B Immunization of Infants: Reactions of Pediatricians and Family Physicians Over Time","volume":"93","author":"Freed","year":"1994","journal-title":"Pediatrics"},{"key":"10.1016\/j.jsps.2022.10.001_b0115","doi-asserted-by":"crossref","first-page":"c7452","DOI":"10.1136\/bmj.c7452","article-title":"Wakefield\u2019s article linking MMR vaccine and autism was fraudulent","volume":"342","author":"Godlee","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jsps.2022.10.001_b0120","unstructured":"Government of Canada, 2019. Adverse events following immunization: Canadian Immunization Guide - Canada.ca [WWW Document]. URL https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-2-vaccine-safety\/adverse-events-following.html#p (accessed 9.1.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0125","doi-asserted-by":"crossref","unstructured":"Grohskopf, L.A., Alyanak, E., Ferdinands, J.M., Broder, K.R., Blanton, L.H., Talbot, H.K., Fry, A.M., 2021. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021\u201322 Influenza Season. MMWR. Recommendations and Reports 70, 1\u201332. https:\/\/doi.org\/10.15585\/MMWR.RR7005A1.","DOI":"10.15585\/mmwr.rr7005a1"},{"key":"10.1016\/j.jsps.2022.10.001_b0130","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1016\/j.vaccine.2017.03.035","article-title":"Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012\u201315","volume":"35","author":"Harris","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jsps.2022.10.001_b0135","doi-asserted-by":"crossref","unstructured":"Hause, A.M., Gee, J., Baggs, J., Abara, W.E., Marquez, P., Thompson, D., Su, J.R., Licata, C., Rosenblum, H.G., Myers, T.R., Shimabukuro, T.T., Shay, D.K., 2020. COVID-19 Vaccine Safety in Adolescents Aged 12\u201317 Years \u2014 United States, December 14, 2020\u2013July 16, 2021.","DOI":"10.15585\/mmwr.mm7031e1"},{"key":"10.1016\/j.jsps.2022.10.001_b0140","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10552-021-01430-4","article-title":"Associations between ACA-related policies and a clinical recommendation with HPV vaccine initiation","volume":"32","author":"Hawkins","year":"2021","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jsps.2022.10.001_b0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"npj Vaccines"},{"key":"10.1016\/j.jsps.2022.10.001_b0150","first-page":"10","article-title":"Human Vaccines 13-valent pneumococcal conjugate vaccine (PCV13). Landes Bioscience 1012","volume":"7","author":"Jefferies","year":"2011","journal-title":"Human Vaccines"},{"key":"10.1016\/j.jsps.2022.10.001_b0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mpdhp.2016.06.005","article-title":"Survival analysis","volume":"22","author":"Kartsonaki","year":"2016","journal-title":"Diagn Histopathol"},{"key":"10.1016\/j.jsps.2022.10.001_b0160","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1016\/j.vaccine.2018.08.085","article-title":"Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines","volume":"37","author":"Kochhar","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jsps.2022.10.001_b0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41467-022-28068-3","article-title":"Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong","volume":"13","author":"Lai","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jsps.2022.10.001_b0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/vaccines8010101","article-title":"Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain-Barr\u00e9 Syndrome","volume":"8","author":"Lee","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jsps.2022.10.001_b0175","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"n1435","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jsps.2022.10.001_b0180","doi-asserted-by":"crossref","first-page":"n1435","DOI":"10.1136\/bmj.n1435","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jsps.2022.10.001_b0185","doi-asserted-by":"crossref","unstructured":"Lauri E. Markowitz, Eileen F. Dunne, Mona Saraiya, Herschel W. Lawson, Harrell Chesson, Elizabeth R. Unger, 2007. Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) [WWW Document]. URL https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5602a1.htm (accessed 2.11.22).","DOI":"10.1037\/e601292007-001"},{"key":"10.1016\/j.jsps.2022.10.001_b0190","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human Papillomavirus Vaccine Introduction \u2013 The First Five Years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jsps.2022.10.001_b0195","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.17.17-00468","article-title":"Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016","volume":"23","author":"Mentzer","year":"2018","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.jsps.2022.10.001_b0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1057\/palgrave.jphp.3190016","article-title":"Regulation of vaccines: strengthening the science base","volume":"25","author":"Milstien","year":"2004","journal-title":"J Public Health Policy"},{"key":"10.1016\/j.jsps.2022.10.001_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jsps.2022.10.001_b0210","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jsps.2022.10.001_b0215","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12911-019-0818-8","article-title":"A statistical analysis of vaccine-adverse event data","volume":"19","author":"Ren","year":"2019","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"10.1016\/j.jsps.2022.10.001_b0220","unstructured":"Ryan Gierke, A. Patricia Wodi, Miwako Kobayashi, 2021. Pinkbook: Pneumococcal Disease | CDC [WWW Document]. URL https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/pneumo.html (accessed 2.11.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/0019-5545.82529","article-title":"The MMR vaccine and autism: Sensation, refutation, retraction, and fraud","volume":"53","author":"Sathyanarayana Rao","year":"2011","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.jsps.2022.10.001_b0230","unstructured":"Schillie, S., Murphy, T.V., Sawyer, M., Ly, K., Hughes, E., Jiles, R., de Perio, M.A., Reilly, M., Byrd, K., Ward, J.W., 2013. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 62."},{"key":"10.1016\/j.jsps.2022.10.001_b0235","first-page":"5","article-title":"Shingrix for Herpes Zoster: A Review","volume":"24","author":"Shah","year":"2019","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jsps.2022.10.001_b0240","doi-asserted-by":"crossref","first-page":"s247","DOI":"10.1093\/cid\/ciq115","article-title":"The Lyme Disease Vaccine\u2014A Public Health Perspective","volume":"52","author":"Shen","year":"2011","journal-title":"Clinical Infect. Dis."},{"key":"10.1016\/j.jsps.2022.10.001_b0245","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jsps.2022.10.001_b0250","unstructured":"VAERS, 1990. VAERS - About Us [WWW Document]. URL https:\/\/vaers.hhs.gov\/about.html (accessed 2.6.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jsps.2022.10.001_b0260","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 Vaccination in a Large Health Care Organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2022.10.001_b0265","unstructured":"World Health Organization (WHO), 2014. Global manual on surveillance of adverse events following immunization. Geneva."},{"key":"10.1016\/j.jsps.2022.10.001_b0270","unstructured":"World Health Organization, 2019. Causality assessment of an adverse event following immunization (AEFI) User manual for the revised WHO classification."},{"key":"10.1016\/j.jsps.2022.10.001_b0275","unstructured":"World Health Organization, 2019. Immunization [WWW Document]. URL https:\/\/www.who.int\/news-room\/facts-in-pictures\/detail\/immunization (accessed 9.7.22)."},{"key":"10.1016\/j.jsps.2022.10.001_b0280","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vaccine.2011.10.076","article-title":"Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA","volume":"30","author":"Zhao","year":"2011","journal-title":"Vaccine"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422002493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422002493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:27:32Z","timestamp":1736166452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016422002493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1319016422002493"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2022.10.001","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.23.22272819","asserted-by":"object"}]},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics\u2019 impact","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}